Please check your internet connection and try again.
# Hepamerz (L-Ornithine L-Aspartate - LOLA)
## Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two endogenous amino acids. It functions by stimulating the urea cycle (ornithine) and the glutamine synthesis pathway (aspartate) in the liver and muscles, facilitating the detoxification of ammonia in patients with hepatic encephalopathy.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy (HE).
* Management of hyperammonemia associated with acute and chronic liver diseases (e.g., cirrhosis, fatty liver, hepatitis).
## Adult Dosing
* **Oral (Granules):** 1–2 sachets (3g per sachet) dissolved in liquid 3 times daily after meals. Maximum: 18g/day.
* **Intravenous (Infusion):** 1–4 ampoules (10g–20g) daily administered as a slow intravenous infusion.
* **Acute/Emergency HE:** Up to 20g daily depending on severity. Must be diluted in IV fluids (e.g., 500mL of Normal Saline or D5W). **Do not exceed infusion rate of 5g per hour.**
## Pediatric Dosing
Safety and efficacy in children are not well-established. Use is generally restricted to specialized pediatric hepatology protocols. If used, dose should be strictly weight-based and determined by a specialist.
## Dose Adjustments
* **Renal Impairment:** Reduce dose in severe renal impairment (Creatinine > 3 mg/dL or estimated GFR < 30 mL/min). Monitor blood/urine urea levels closely as LOLA lacks direct nephrotoxicity but urea metabolites may accumulate.
* **Hepatic Impairment:** No standard reduction required, as it is used to treat hepatic failure.
## Contraindications
* Known hypersensitivity to L-Ornithine or L-Aspartate.
* Severe renal insufficiency (renal failure/anuria, unless under intensive monitoring).
## Adverse Effects
* **Gastrointestinal:** Nausea, vomiting, stomach pain, flatulence, or diarrhea (more common with oral granules).
* **Neurological:** Rare reports of headache or dizziness.
* **Systemic:** Injection site reactions (if IV infusion is too rapid).
## Key Drug Interactions
* No major high-risk drug-drug interactions.
* Concomitant use with other medications lowering serum ammonia (e.g., Lactulose, Rifaximin) is common and generally safe, though monitor for additive therapeutic effects which may necessitate dose adjustments of other ammonia-lowering therapies.
## Monitoring
* **Clinical:** Monitor neurological status (e.g., Number Connection Test, West Haven criteria) for improvement in HE symptoms.
* **Laboratory:** Serum ammonia levels (though clinical correlation is often poor), serum creatinine/BUN (especially in renal impairment).
## Clinical Pearls
* **IV Administration:** Ensure infusion is slow. High-speed infusion can lead to nausea and vomiting.
* **Solubility:** IV solution should be clear. If the solution becomes cloudy or discolored, discard immediately.
* **Stability:** Hepamerz is considered an adjunctive therapy; it does not replace the gold standard management of HE (Lactulose/Rifaximin) in most clinical guidelines.
* **Local Protocol:** Dosing may vary significantly by institution; always consult local pharmacy guidelines or hepatology protocols prior to administration.
***
**Educational Disclaimer:** This information is for educational purposes only and does not replace professional medical judgment. Always verify current prescribing information, institutional protocols, and specific patient contraindications before administering any medication.
